Mesoblast reports $115 million Ryoncil revenue
- Mesoblast reported preliminary Ryoncil revenue of US$115 million for the year ended June 30, 2026.
- The company reported US$36 million in revenue for the latest quarter, with figures subject to audit procedures.
- Mesoblast said it expects further Ryoncil growth as adoption expands across U.S. pediatric treatment centers.
Mesoblast (NASDAQ:MESO) reported preliminary net revenue of US$115 million from Ryoncil for the full year ended June 30, 2026, including US$36 million in the fourth quarter, as the company continues commercial expansion of the therapy.
The revenue result compares with Mesoblast’s earlier projections, with management stating that sales exceeded initial expectations as Ryoncil adoption increased across major U.S. pediatric centers.
Mesoblast said its financial position remains supported by revenue growth and a new five-year financing facility, which the company plans to use for strategic initiatives, including potential label extensions and development of additional products.
The company said Ryoncil revenue growth is expected to continue in fiscal 2027.
Ryoncil, also known as remestemcel-L-rknd, is a mesenchymal stromal cell therapy approved by the U.S. Food and Drug Administration for children under 12 with steroid-refractory acute graft-versus-host disease.
Mesoblast develops cell-based medicines across areas including inflammatory diseases, immune disorders and regenerative medicine, with Ryoncil representing its first commercial product in the United States.
